BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (NASDAQ:BIOA) based on the company’s drug candidate azelaprag that aims to increase weight-loss while improving body composition ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy September 26, 2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug ...

BioAge Labs, Inc. ( (BIOA)) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. BioAge Labs, Inc. is a clinical-stage biotechnology ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge",“the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...